Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Tongji Hospital have disclosed sulfonylurea compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of heart failure.
Merck & Co. revealed the structure of an orally active and potent proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor macrocyclic peptide, MK-0616, which is being developed for the potential treatment of hypercholesterolemia and atherosclerosis.
(Azacycloalkyl)methoxy-substituted benzamides acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists have been described in a recent Accellena Research and Development LLC patent.
Accellena Research and Development LLC has identified substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists reported to be useful for the treatment of cardiovascular disorders, diabetes, metabolic diseases, migraine, neurological disorders, obesity, psychiatric disorders and substance abuse and dependence.
Researchers from Baylor College of Medicine presented data from postnatal testing with the aim of providing molecular diagnosis for a patient with prenatally diagnosed heterotaxy syndrome.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified dual antagonists of endothelin ETA receptor and angiotensin AT1 receptor reported to be useful for the treatment of diabetes, hypertension and renal disorders.
Homozygous familial hypercholesterolemia (HoFH) is a severe rare life-threatening condition where high blood levels (>500 mg/dL) of low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and premature and progressive atherosclerotic cardiovascular disease (ASCVD) are the main features.
RSS
